<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05079399</url>
  </required_header>
  <id_info>
    <org_study_id>11656</org_study_id>
    <nct_id>NCT05079399</nct_id>
  </id_info>
  <brief_title>Biomarker of Diabetic Retinopathy</brief_title>
  <official_title>Biomarker of Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic retinopathy (DR) is a complication of diabetes in which blood vessels supplying&#xD;
      blood to the back of the eye (retina) are dysfunctional. This can lead to an improper supply&#xD;
      of oxygen and nutrients to the retinal tissue, or it may trigger the formation of new blood&#xD;
      vessels in response to the oxygen/nutrient deficiency. Ultimately affecting the normal&#xD;
      vision. There is no known marker that will provide information on the health status of&#xD;
      retinal blood vessels. Using highly specialized cells in the blood, this study will try to&#xD;
      discover a marker of DR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mRNA and miRNA sequencing of circulating angiogenic cells isolated from study participants</measure>
    <time_frame>Baseline and change in RNA signature in follow up visit (between 3-5 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Surface marker expression of inflammatory markers using flow cytometry</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>miRNA expression</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Epigenetic changes in circulating angiogenic cells with different severities of diabetic retinopathy</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early Treatment Diabetic Retinopathy Study (ETDRS) clinical scoring in wide-field fundus photography</measure>
    <time_frame>Baseline and follow up visit (between 3-5 years)</time_frame>
    <description>The scoring will be between 10 (no retinopathy) and 85 (advanced proliferative diabetic retinopathy). Higher score means worst outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence or absence of neovascularization and total area of non-perfusion in fluorescein angiography (FA)</measure>
    <time_frame>Baseline and follow up visit (between 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in vessel density in optical coherence tomography angiography (OCT-A)</measure>
    <time_frame>Baseline and follow up visit (between 3-5 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in retinal thickness in optical coherence tomography angiography (OCT-A)</measure>
    <time_frame>Baseline and follow up visit (between 3-5 years)</time_frame>
  </secondary_outcome>
  <number_of_groups>6</number_of_groups>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetes but no retinopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild non proliferative diabetic retinopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate non proliferative diabetic retinopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe non proliferative diabetic retinopathy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Proliferative diabetic retinopathy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Blood samples will be collected via venipuncture</description>
    <arm_group_label>Diabetes but no retinopathy</arm_group_label>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_label>Mild non proliferative diabetic retinopathy</arm_group_label>
    <arm_group_label>Moderate non proliferative diabetic retinopathy</arm_group_label>
    <arm_group_label>Proliferative diabetic retinopathy</arm_group_label>
    <arm_group_label>Severe non proliferative diabetic retinopathy</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Ribonucleic acid (RNA)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We will recruit type 2 diabetes individuals with different severities of diabetic&#xD;
        retinopathy and non-diabetes controls.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability to cooperate with imaging procedures.&#xD;
&#xD;
          -  Health status: established type 2 diabetes&#xD;
&#xD;
          -  No history of panretinal photocoagulation (PRP)&#xD;
&#xD;
          -  No history of treatment with intravitreal agents for past 12 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or current malignancy&#xD;
&#xD;
          -  Acute or chronic infection (HIV, hepatitis B or C, tuberculosis)&#xD;
&#xD;
          -  Cerebral vascular accident or cerebral vascular procedure&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  Presence of a graft (to avoid any effect of the graft)&#xD;
&#xD;
          -  History of previous vitrectomy&#xD;
&#xD;
          -  Subjects with a history of age-related macular degeneration age-related macular&#xD;
             degeneration (AMD), glaucoma, uveitis, and branched or central vein occlusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Ashay D Bhatwadekar, PhD, RPh</last_name>
    <phone>3172785075</phone>
    <email>abhatwad@iupui.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amir R Hajrasouliha, MD</last_name>
    <phone>3179441154</phone>
    <email>amhajras@iu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Spring Mill Clinic</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46920</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amir R Hajrasouliha, MD</last_name>
      <email>amhajras@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eskenazi Eye Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amir R Hajrasouliha, MD</last_name>
      <email>amhajras@iu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glick Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Amir R Hajrasouliha, MD</last_name>
      <phone>317-944-1154</phone>
      <email>amhajras@iu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Ashay Bhatwadekar, PhD, RPh</investigator_full_name>
    <investigator_title>Associate Professor Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

